Hypertension therapy: mixing, matching, and meeting targets.
The inappropriate control of hypertension is a public health problem worldwide. It is notable that although there are several causes for this situation, lack of effective pharmacotherapy is not among them. It has long been known that combinations of antihypertensive drugs are highly effective in most patients; the problem is implementing treatment recommendation guidelines into clinical practice with the most effective and best tolerated therapies. The latest guidelines on therapies for hypertension from the World Health Organization/International Society of Hypertension, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (US), and the European Societies of Hypertension and Cardiology consistently emphasize this need of combination treatments in a large part of the hypertensive patient population. This review focuses on the combination of one of the oldest drugs, thiazide diuretics, with one of the youngest, angiotensin-receptor blockers, and analyzes the available literature regarding potential applications in specific populations. This represents one of the most widely used, rational and effective combination therapies, combining excellent control of blood pressure with unequalled tolerability. In addition, angiotensin-receptor blocker/diuretic combinations may have cardiovascular benefits beyond those from blood pressure lowering itself.
Faculty of Medicine, University of Rome La Sapienza, Osp. Sant'Andrea-IRCCS Neuromed-Pozzilli (IS), Rome, Italy.
Massimo
M
Volpe
D000368:Aged; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001581:Benzothiadiazines; D048909:Diabetes Complications; D004232:Diuretics; D004359:Drug Therapy, Combination; D005006:Ethnicity; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage*
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors